Navigation Links
Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

ll differentiation and cell survival. KRX-0401 is currently in a Phase 3 trial, under Special Protocol Assessment (SPA), in multiple myeloma, and in Phase 2 clinical development for several other tumor types. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401; the risk that the data (both safety and efficacy) from the Phase 3 trial will not coincide with the data analyses from the Phase 1 / 2 clinical trial previously reported by the Company; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Oct. 20, 2014  ResMed (NYSE: ... ResMed Data Exchange program, a comprehensive suite of ... (HME) and other health care providers. ... to critical patient information. It integrates valuable sleep ... U-Sleep™ patient management platforms with customers, in-house or ...
(Date:10/20/2014)... , Oct. 20, 2014   BioNano Genomics ... system: the ability to collect human data at 30X depth, ... single chip.  This new capability was established and demonstrated for ... Irys TM System and will be rolled ... months. BioNano will be showcasing this advancement at the ...
(Date:10/20/2014)... 20, 2014   Taiho Oncology, Inc. , ... Japan ), announced that the U.S. ... designation for TAS-102 (nonproprietary names: trifluridine and tipiracil ... for the treatment of refractory metastatic colorectal cancer ... rolling NDA submission to the FDA. According to ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader ... Tech International (PTI), a joint venture of its subsidiary ... sales agreement with Cure Hands, a company of international ... agreement, Pharma Tech International, the exclusive distributor of CellerateRX® ...
... May 16, 2011 UBM Canon,s medical device publishing ... for the remainder of 2011. (Logo: ... an exciting list of comprehensive content topics that encompass ... outsourcing," stated Rich Nass, Director of Content for the ...
Cached Medicine Technology:International Sales Agreement Signed by WNDM Subsidiary; $500K First-Year Sales Commitment 2International Sales Agreement Signed by WNDM Subsidiary; $500K First-Year Sales Commitment 3International Sales Agreement Signed by WNDM Subsidiary; $500K First-Year Sales Commitment 4UBM Canon Medical Device Content Team Announces Upcoming Virtual Event Content Topics 2UBM Canon Medical Device Content Team Announces Upcoming Virtual Event Content Topics 3
(Date:10/20/2014)... 2014 T.E.N., a technology and ... today that William H. Murray, renowned author and ... Luminary Leadership Award winner. Presented annually, the ISE® ... outstanding leader and industry practitioner for his or ... the information security industry. , Formerly with IBM, ...
(Date:10/20/2014)... 2014 Principle Business Enterprises, a family ... manufacturing top-of-the-line absorbent products. The company has recently ... popular brand, Tranquility® Premium Protection absorbent products. The ... gave its packaging a new look, and is currently ... to the public. , The new website, developed with ...
(Date:10/20/2014)... October 20, 2014 Based on ... the only imaging assays capable of determining DNA ... test.  With these three dimensions of high-resolution data, ... detect the widest range of disease-causing genetic rearrangements, ... by other genomic tools, including today‚Äôs advanced sequencing ...
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 Punzoné ... introduced in the U.S., has a lot to celebrate this ... our country recognizes the achievements and contributions of Americans of ... anniversary for Punzoné, and today it shares its favorite Italian ... a trip to Italy - even if it is only ...
(Date:10/19/2014)... Recently, BambooIndustry.com, one of the most popular suppliers of ... bamboo deckings . Moreover, the company has launched a ... available at deeply discounted rates. , As is ... the significance of online business nowadays. Thus, BambooIndustry.com pays ... workers are striving to deliver both value and efficiency ...
Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2
... The Elton John AIDS Foundation announced today that Grammy-nominated ... Elton John AIDS Foundation (EJAF) Academy Awards(R) Viewing Party ... Center in Los Angeles. The event will be co-hosted ... be co-sponsored by Chopard, Jo & Raffy Manoukian, and ...
... Feb. 4 MedCath Corporation,(Nasdaq: MDTH ), a ... and treatment of cardiovascular disease,today announced its operating results for ... , , Highlights, -- ... 2008, -- Adjusted EBITDA of $17.2 million, ...
... Pharmaceutical Research and Manufacturers of America (PhRMA) President ... today regarding the State Children,s Health Insurance Program ... of the State Children,s Health Insurance Program (SCHIP) ... uninsured American families and, indeed, for all Americans ...
... SCHIP Law Will Tax Little Cigars at Cigarette Equivalent ... the Maxwell Report indicates a dramatic increase in the ... decade, a troubling trend given the popularity of these ... American community. According to the data, over a ...
... as often as others, study finds , , , WEDNESDAY, ... forcing millions of insured and uninsured cancer survivors in ... they need, a new analysis reveals. , What,s more, ... are twice as likely as white survivors to forgo ...
... Researchers say first two years of combined hormone therapy a ... new analysis shows that the drop in breast cancer cases ... hormone replacement therapy (HRT) after a large, U.S. study showed ... users of some kinds of HRT. , Some experts have ...
Cached Medicine News:Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 2Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 3Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 4Health News:MedCath Corporation Reports First Quarter Earnings 2Health News:MedCath Corporation Reports First Quarter Earnings 3Health News:MedCath Corporation Reports First Quarter Earnings 4Health News:MedCath Corporation Reports First Quarter Earnings 5Health News:MedCath Corporation Reports First Quarter Earnings 6Health News:MedCath Corporation Reports First Quarter Earnings 7Health News:MedCath Corporation Reports First Quarter Earnings 8Health News:MedCath Corporation Reports First Quarter Earnings 9Health News:MedCath Corporation Reports First Quarter Earnings 10Health News:MedCath Corporation Reports First Quarter Earnings 11Health News:MedCath Corporation Reports First Quarter Earnings 12Health News:MedCath Corporation Reports First Quarter Earnings 13Health News:MedCath Corporation Reports First Quarter Earnings 14Health News:PhRMA Statement on Expansion of SCHIP 2Health News:Little Cigar Consumption on the Rise, While Cigarette Use Declines 2Health News:Little Cigar Consumption on the Rise, While Cigarette Use Declines 3Health News:Little Cigar Consumption on the Rise, While Cigarette Use Declines 4Health News:Cancer Survivors Say Costs Keep Them From Care 2Health News:Cancer Survivors Say Costs Keep Them From Care 3Health News:Cancer Survivors Say Costs Keep Them From Care 4Health News:Drop in Breast Cancer Rates Due to Drop in HRT Use 2Health News:Drop in Breast Cancer Rates Due to Drop in HRT Use 3
Orthofix's retrograde nail provides easier insertion of nail by rotational movements....
... design philosophy of the Quad 4™ Intramedullary ... system that could be used for the ... requirements of the system were to minimize ... complete inventory, with one system that could ...
... Fast and easy voice access to information ... SoundAdvice is easy and intuitive, enabling you ... your keyboard. With the VoiceBox Voice Information ... about hundreds of subjects and topics and ...
... Magnetic stimulation is a non-invasive and ... central nervous system. Cadwell Laboratories manufactures two ... High Speed Magnetic Stimulator (HSMS). The Hight ... stimulation rates up to 25 Hz at ...
Medicine Products: